Dr. Bezerra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-7526
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2019 - 2022
University of WashingtonResidency, Internal Medicine, 2016 - 2019- University of Washington School of MedicineFellowship, Bmt, 2014 - 2014
University of Sao PauloFellowship, Hematology, 2012 - 2014- University of Sao PauloResidency, Internal Medicine, 2010 - 2012
- Universidade Federal do Rio Grande do NorteClass of 2009, MD
Certifications & Licensure
OH State Medical License 2022 - 2026
MN State Medical License 2019 - 2023
WA State Medical License 2014 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Abstract achievement award American Society of Hematology, 2017
Publications & Presentations
PubMed
- Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis.Amneet Bajwa, Qiuhong Zhao, Marcus J Geer, Chenyu Lin, James Westholder
Blood Advances. 2024-10-22 - Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra
Leukemia & Lymphoma. 2024-10-12 - SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
Press Mentions
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients with Aggressive Blood CancersDecember 13th, 2023
Other Languages
- Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
